INTRODUCTION
COPD is an important lung and airway disease with an increasing incidence particularly in developing countries. Worldwide, asthma and COPD affect the lives of ~300 and 200 million people, respectively (1) . COPD is a chronic inflammatory disease for which smoking is the major risk factor in the developed world and is currently the fourth leading cause of death worldwide. It is predicted to become the third ranked disease by the year 2030 (2, 3) . Unfortunately, there are no effective treatments for severe asthma and COPD due to a lack of clarity in disease mechanisms. However, new observations in the areas of signal transduction and epigenetics may provide new understanding of the pathogenesis of lung diseases. Understanding the pathways and mechanisms leading to mediator release may lead to better therapeutic approaches for these diseases. The inflammatory mediators involved in COPD have not been clearly delineated but are thought to include many lipid mediators, inflammatory peptides, reactive oxygen species (ROS) and nitrogen species, chemokines, cytokines and growth factors. These are 
Potential role of signal transduction pathways as putative therapeutic targets in pathogenesis of COPD
Understanding the pathways and mechanisms leading to mediator release may lead to better therapeutic approaches for this disease. With the complexity of inflammatory signaling networks and the cross talk that occurs between them, it is important to develop a greater understanding of these networks in the pathogenesis of disease. In terms of lung disease, it is still debatable whether these diseases occur as a result of excessive inflammatory drive or a lack of inhibitory feedback loops. However, it is clear that many of these pathways/networks are abnormally activated in COPD and that interference with these signaling pathways could shed light on disease processes and provide novel therapeutic approaches. Among signaling pathways involved in pathogenesis of COPD, Toll Like Receptors (TLRs) and Inflammasome NALP3 signal transduction activation have been described (40) (41) (42) .
In this regard, increased ROS production by cigarette smoke has been directly linked to oxidation of proteins, DNA, and lipids which may cause direct lung injury or induce a variety of cellular responses through the generation of highly reactive secondary metabolic entities. ROS may alter remodeling of extracellular matrix, apoptosis and mitochondrial respiration, cell proliferation, maintenance of surfactant and the antiprotease screen, effective alveolar repair response and immune modulation in the lungs (43, 44) . ROS have also been implicated in initiating the lung inflammatory response through the activation of transcription factors such as NF-B and AP-1 and the regulation of the expression and activity of histone modifying enzymes and thereby enhancing inflammatory gene expression (45) . Activation of ROS pathways in pathogenesis of asthma (46) (47) (48) and COPD has been described (49-51).
Importantly, growing evidence indicates a role for ROS in the activation of TLR pathways (52) (53) (54) and NALP3 inflammasome (55) (56) (57) .
Besides ROS, increased ATP levels in in-vitro, invivo models and preclinical smoke-exposure models have been reported (58, 59) . ATP can activate the NLRP3 Inflammasome through the P2X7 receptor (60) (61) (62) and, in addition, regulate neutrophil chemotaxis and activation through P2Y receptors (63, 64) .
Finally, the expression of the NLRP3 Inflammasome-associated cytokines IL-1 and IL-18 is increased in the lungs of COPD patients and animals exposed to cigarette smoke (65, 66) . IL-1β levels are increased in airway secretions during COPD exacerbations (66) and correlate significantly with disease severity and other inflammatory mediators such as TNF-α and IL-8 (67) . Furthermore, IL-1β can induce the release of M-CSF and GM-CSF from inflammatory cells (68) which in turn potentiates induction of chronic inflammatory diseases (Figure 1 ).
GENERAL CONCLUSIONS
Taken together, we conclude that a key process in the pathogenesis of COPD involves ROS/ATPmediated activation of the NALP3 inflammasome and TLRs leading to prolonged, inflammatory responses. 
